ArticleRenal failure2025
Novel obesity biomarkers as mortality predictors in individuals with CKD: a comparative analysis with traditional anthropometric measures.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The a body shape index (ABSI) and body roundness index (BRI) represent novel obesity biomarkers. This study aimed to determine their predictive capabilities for mortality risk in individuals with chronic kidney disease (CKD) and to compare their performance with traditional obesity markers of body mass index (BMI) and waist circumference (WC). We performed a cohort study by analyzing 6,577 adult CKD participants (mean age 60.372 years, 43.588% men) from the 1999-2018 National Health and Nutrition Examination Survey. We determined the prognostic value of ABSI and BRI for all-cause and cardiovascular disease (CVD) mortality using the Cox proportional hazard regression analysis. We also compared the predictive performance between ABSI, BRI and BMI and WC by time-dependent receiver-operating characteristic curves. The cohort experienced 2,532 (31.7%) deaths, including 921 CVD mortality, over a median of 90 months. Compared to the lowest quartile, the hazard ratios (95% confidence intervals) for the highest quartile of ABSI and BRI were 3.320 (2.803-3.934) and 1.157 (1.019-1.315), respectively, for all-cause mortality, and 3.796 (2.971-4.850) and 1.319 (1.041-1.671), respectively, for CVD mortality. Dose-response analysis revealed a positive and linear relationship between ABSI and mortality. A nonlinear relationship was identified between BRI with all-cause and CVD mortality. ABSI consistently outperformed BRI, BMI, and WC in predicting all-cause and CVD mortality across almost all follow-up periods. Thus, ABSI emerges as a promising obesity biomarker for predicting all-cause and CVD mortality risk in US adults with CKD, supporting its incorporation into routine CKD prognostication assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.